Select publications
De Gramont A et al. Targeted agents for adjuvant therapy of colon cancer. Semin Oncol 2006;33(Suppl 11):42-5. Abstract
Hambleton J et al. Safety of low-dose aspirin (ASA) in a pooled analysis of 3 randomized, controlled trials (RCTs) of bevacizumab (BV) with chemotherapy (CT) in patients (pts) with metastatic colorectal cancer (mCRC). Proc ASCO 2005;Abstract 3554.
Hambleton J et al. Bevacizumab does not increase bleeding in patients with metastatic colorectal cancer receiving concurrent anticoagulation. Proc ASCO 2004;Abstract 3528.
Hedrick E et al. Safety of bevacizumab plus chemotherapy as first-line treatment of patients with metastatic colorectal cancer: Updated results from a large observational registry in the US (BRiTE). Proc ASCO 2006;Abstract 3536.
Hochster HS. Bevacizumab in combination with chemotherapy: First-line treatment of patients with metastatic colorectal cancer. Semin Oncol 2006;33(5 Suppl 10):8-14. Abstract
Hurwitz H et al. Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) prolongs survival in first-line colorectal cancer (CRC): Results of a phase III trial of bevacizumab in combination with bolus IFL (irinotecan, 5-fluorouracil, leucovorin) as first-line therapy in subjects with metastatic CRC. Proc ASCO 2003;Abstract 3646.
Kabbinavar FF et al. Combined analysis of efficacy: The addition of bevacizumab to fluorouracil/ leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 2005;23(16):3706-12. Abstract
Skillings JR et al. Arterial thromboembolic events (ATEs) in a pooled analysis of 5 randomized, controlled trials (RCTs) of bevacizumab (BV) with chemotherapy. Proc ASCO 2005;Abstract 3019.
